- Home
- CURI vs ERAS Comparison
CURI vs ERAS Comparison
Compare CURI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- ERAS
- Stock Information
- Founded
- CURI N/A
- ERAS 2018
- Country
- CURI United States
- ERAS United States
- Employees
- CURI N/A
- ERAS N/A
- Industry
- CURI Movies/Entertainment
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- ERAS Health Care
- Exchange
- CURI Nasdaq
- ERAS Nasdaq
- Market Cap
- CURI 394.5M
- ERAS 348.4M
- IPO Year
- CURI N/A
- ERAS 2021
- Fundamental
- Price
- CURI $4.98
- ERAS $1.37
- Analyst Decision
- CURI Strong Buy
- ERAS Strong Buy
- Analyst Count
- CURI 2
- ERAS 6
- Target Price
- CURI $5.40
- ERAS $4.83
- AVG Volume (30 Days)
- CURI 741.4K
- ERAS 1.7M
- Earning Date
- CURI 08-12-2025
- ERAS 08-11-2025
- Dividend Yield
- CURI 4.57%
- ERAS N/A
- EPS Growth
- CURI N/A
- ERAS N/A
- EPS
- CURI N/A
- ERAS N/A
- Revenue
- CURI $54,223,000.00
- ERAS N/A
- Revenue This Year
- CURI $24.74
- ERAS N/A
- Revenue Next Year
- CURI $13.30
- ERAS N/A
- P/E Ratio
- CURI N/A
- ERAS N/A
- Revenue Growth
- CURI N/A
- ERAS N/A
- 52 Week Low
- CURI $0.99
- ERAS $1.01
- 52 Week High
- CURI $7.15
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CURI 42.59
- ERAS 46.81
- Support Level
- CURI $4.74
- ERAS $1.31
- Resistance Level
- CURI $4.98
- ERAS $1.59
- Average True Range (ATR)
- CURI 0.42
- ERAS 0.13
- MACD
- CURI -0.23
- ERAS -0.02
- Stochastic Oscillator
- CURI 12.43
- ERAS 25.00
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.